Merck Sharp + Dohme Corp.

Microsoft Technology Licensing, LLC

Fred Hutchinson Cancer Center

Rosetta Inpharmatics, Inc.

The Netherlands Cancer Institute

Nederlands Kanker Instituut

Microsoft Corporation

Hongyue Dai

John R Thompson

Yudong He

Joel Peter Berger

Laura Johanna Van't Veer

Pek Yee Lum

Richard F Raubertas

Kenny Kin Chung Wong

Eric Stanley Muise

Yejun Tan

Peter S Linsley

Stephen H Friend

Roland Stoughton

Lee Weng

Steven Bartz

Christopher J Roberts

Mao Mao

Janell M Schelter

Jerald P Radich

John Lamb

Rene Bernards

A A Hart

In one aspect, the present invention provides methods of determining whether an agent is more like a partial agonist of a target molecule than a full agonist of the same target molecule. In another aspect, the present invention provides methods to select a candidate compound that may reduce blood plasma glucose concentration in a mammal. Populations of genes are provided that are useful in the practice of the present invention.

Methods for characterizing agonists and partial agonists of target molecules

The present invention provides methods and computer programs for detecting variations in measurements of a biological variable, e.g., variations in cell viability, under different conditions, e.g., with or without treatment of a drug, under the treatments of different drugs, or under different environmental conditions. The methods and programs of the invention determine a metric of difference between measurements under different condition, and make use of predetermined errors of the measurements, e.g., errors determined from an error model, to estimate the errors in the metric of difference. Such an approach provides a more accurate estimate of the errors of measurements, which, in turn, provides a more accurate estimate of the error of the difference metric.

Methods and computer systems for analyzing high-throughput assays

The present invention relates to genetic markers whose expression is correlated with colon cancer. In one aspect, the invention provides sets of markers whose expression can be used for classifying colon cancer patients into different prognostic categories. In another aspect, the invention provides kits containing marker sets for determining prognosis of colon cancer. In another aspect, the invention provides methods of classifying cancer patients with regard to prognosis.

Methods for diagnosis and/or prognosis of colon cancer

The present invention provides prognostic methods for conditions such as cancer, for example, breast cancer, comprising classifying an individual by a plurality of phenotypic, genotypic or clinical characteristics of the condition into a plurality of patient subsets, and analyzing the pattern of expression of prognosis-informative genes identified for that subset in a sample from the individual. The present invention also provides methods for constructing such patient subsets and of identifying prognosis-informative genesets for such subsets. The invention further provides methods of assigning a therapeutic regimen to an individual, microarrays useful for performing prognosis, kits comprising these microarrays, and computer systems and programs for implementing the methods of the invention.

Classification of breast cancer patients using a combination of clinical criteria and informative genesets

The invention provides molecular markers that are associated with the progression of chronic myeloid leukemia (CML), and methods and computer systems for monitoring the progression of CML in a patient based on measurements of these molecular markers. The present invention also provides CML target genes, and methods and compositions for treating CML patients by modulating the expression or activity of these CML target genes and/or their encoded proteins. The invention also provides genes that are associated with resistance to imatinib mesylate (Gleevec&#x2122;) treatment in CML patients, and methods and compositions for determining the responsiveness of a CML patient to imatinib mesylate treatment based on measurements of these genes and/or their encoded proteins. The invention also provides methods and compositions for enhancing the effect of Gleevec&#x2122; by modulating the expression or activity of these genes and/or their encoded proteins.

Genes associated with progression and response in chronic myeloid leukemia and uses thereof

Growing community of inventors

Kenmore, WA, United States of America

Hongyue Dai